New Treatments for HIV Patients With Low Immune Cell Counts
Part of Immune system & allergy, Infections clinical trials.
This study tests targeted therapies to help HIV patients whose immune systems haven't fully recovered despite years of successful HIV medication. You may qualify if your CD4 count (a measure of immune health) stays low even though your viral load is undetectable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- On HIV medications (ART) for more than 4 years with undetectable viral load for 3+ years
- CD4 count persistently below 350 cells/μL despite successful HIV treatment
- Currently taking dolutegravir-based HIV regimen for at least 1 year with no resistance
- Willing to continue current HIV medications and stay in study for at least 1 year
- No co-infections (hepatitis B, C, or other serious viruses) or severe immune-suppressing conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding Qiling Yiqi Tablets (a Chinese herb formula) to your usual HIV medications can help people whose immune system hasn't fully recovered despite having undetectable HIV. It is for people with a specific TCM diagnosis called lung-spleen qi deficiency.
This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.
This trial tests if adding a Chinese herbal medicine (Fuyang Jiedu Granules) to your regular HIV treatment can help raise your CD4 count. It's for people whose CD4 count stays low even after years of successful HIV treatment.
This study looks at whether certain HIV drug resistance mutations affect how well your immune system recovers after starting HIV treatment. You may qualify if you are newly diagnosed, have never taken HIV meds before, and have a drug resistance test result available.
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
This trial tests a new drug called JL18008 (a man-made form of Interleukin-7) to see if it can help increase CD4 immune cells in people with HIV who are on effective antiretroviral therapy but have persistently low CD4 counts (between 100 and 350). It aims to improve immune function.
Hear when a new Immunological Non-Responders in People With HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.